Your source for answers to the complex challenges of cell and gene therapy development. Building on the topic of rare diseases in our earlier blog, Labcorp cell and gene therapy leadership shared their insights on strategies for overcoming key challenges in rare disease studies in pediatric populations along with their …
Cell and Gene Therapy Answers: Advancing treatments for pediatric patients with rare diseases
Your source for answers to the complex challenges of cell and gene therapy development. Labcorp’s cell and gene therapy scientific leaders shared their insights on the factors that make rare and pediatric diseases a good fit for cell and gene therapy, along with the key challenges and best practices in …
Meeting an Unprecedented Surge in Demand for Kit Production
Supply chain disruptions and manufacturing shortages have significantly affected the clinical trial industry, an issue exacerbated by an unprecedented demand for clinical trial kits. To help maintain business continuity, the Labcorp Central Laboratories team had to develop creative operational solutions at every step of production and quickly accelerate the launch …
Cell and gene therapy answers: Assessing the critical quality attributes, challenges and importance of CMC
Your source for answers to the complex challenges of cell and gene therapy development. Labcorp shares an introduction to CMC, key analytical methods used in assessing the Critical Quality Attributes, challenges in developing these assays and thoughts on the road ahead over the next 5-10 years. What is CMC and …
Technologies, tools and processes to support patient-centric oncology trials
There is a gap between the number of patients needed to participate in new cancer trials and the number who give consent to take part. Decentralized clinical trials (DCTs) are helping to address this gap by increasing the reach of clinical studies beyond conventional research sites. DCTs provide an opportunity …
Exploring Decentralized Clinical Trials (DCTs) – a new monthly blog series
Welcome to the Decentralized Clinical Trials (DCTs) monthly blog. With patient-centric trial designs becoming a driving force in the drug development industry, we will be doing a series of monthly blogs that look back on recent events which give us insight into designing resilient clinical trials and ensuring study and …
Understanding vendor management challenges in Decentralized Clinical Trials (DCT, aka Hybrid and Virtual Trials)
The purported benefits of decentralized clinical trials (DCT) include accelerated enrollment, reduced patient burden and improved retention rates, among other efficiencies. Incorporating virtual elements into the traditional trial model requires a clear vision for the technologies, platforms and other “site-less” elements that support these efforts; however, the potential challenges of …
Labcorp delivers unmatched COVID-19 diagnostic and therapeutic applications
We’re in this together: How they are delivering unmatched acceleration of COVID-19 diagnostic and therapeutic applications Accelerating much needed COVID-19 testing, vaccines and treatment options across the world can’t be done alone. We’re in this together and ready to apply our unique combination of solutions that blend Covance and Labcorp’s …
Incorporating the patient voice to improve ulcerative colitis recruitment
The exact cause of ulcerative colitis (UC) is still unknown, but approximately 700,000 people in the United States suffer from this chronic, life-long disease that causes inflammation in the large intestine. A wide range of treatment options are available, but drug development sponsors are seeking additional ways to control inflammation, …
Approaches to Accommodate a Wide Range of Asthma Patients
Controlling exposure often helps patients with asthma, a common condition that is often managed with self-care and inhalers. While many treatment options can manage a patient’s symptoms and ameliorate asthma and asthma attacks, ongoing clinical trials seek to improve the safety and efficacy of existing treatments and find new solutions …